Cover Image
Market Research Report

Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast-2030

Published by DelveInsight Business Research LLP Product code 955868
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast-2030
Published: July 1, 2020 Content info: 100 Pages
Description

DelveInsight's 'Non-muscle Invasive Bladder Cancer (NMIBC)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted NMIBC epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Non-muscle Invasive Bladder Cancer (NMIBC) Understanding

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved.

NMIBC, formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence and that often requires lifelong surveillance.

The bladder is a vessel that stores urine produced by the kidneys before excretion. The bladder itself is made up of several tissue layers. The first two layers include the urothelial and the lamina propria layers. The urothelial or mucosal layer makes contact with the bladder contents, while the lamina propria, or submucosal layer, and connects the urothelial layer to the underlying smooth muscle. Bladder cancer is a common malignancy arising from the urothelial cells and is responsible for considerable morbidity and mortality. The most common symptom of bladder cancer is hematuria, which occurs in 80-90% of patients. Approximately 70% of newly diagnosed cases of bladder cancer are NMIBC, meaning that they are confined to the urothelial and lamina propria layers of the bladder. Among NMIBCs, around 70% present as Ta lesions (papillary tumor confined to the urothelium), 20% as T1 lesions (tumor invades the lamina propria), and 10% as carcinoma in situ (CIS) (flat, high-grade tumor confined to the urothelial layer).

Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent cases of Bladder Cancer, Diagnosed Prevalent cases of Bladder cancer, Diagnosed Prevalent cases of NMIBC, Age-specific Diagnosed Prevalence of NMIBC, Tumor (T) stage-specific Diagnosed Prevalence of NMIBC, Grade-specific Diagnosed Prevalence of NMIBC, and Risk-specific Diagnosed Prevalence of NMIBC a scenario of NMIBC in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

NMIBC Detailed Epidemiology Segmentation

  • In the 7MM, the total diagnosed prevalent population of NMIBC was estimated to be 533,263 cases in 2017, which is expected to increase in the forecast period
  • The United States accounted for the maximum diagnosed prevalent population among the 7MM in 2017.
  • In EU5 countries, Germany accounted for the highest diagnosed cases of NMIBC while United Kingdom had the lowest diagnosed prevalent population in 2017.
  • In the United States, there were 6,841, 58,791, 125,919 and 22,234 cases for >44, 45-64, 65--84 and >85 years, in 2017 which is expected to rise in the forecast period.
  • There are different stages in which NMIBC is classified which include Ta (lowest stage), Stage Tis and Stage T1. Over half of patients with low-grade Ta cancers will have a tumor recurrence. In 2017, the diagnosed prevalent population of stage Ta, low grade NMIBC was 134,684 and stage Ta, high grade NMIBC was 14,965 in the United States.
  • In 2017, the diagnosed prevalent population of high risk NMIBC was 26,366 and low risk NMIBC was 48,325 in Japan.

Scope of the Report:

  • The report covers the descriptive overview of NMIBC, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of NMIBC.
  • The report provides the segmentation of the disease epidemiology for 7MMby Total Prevalent Cases of NMIBC, Total Diagnosed and Treated Cases of NMIBC.

Report Highlights:

  • Eleven-Year Forecast of NMIBC
  • 7MM Coverage
  • Prevalent cases of Bladder Cancer
  • Diagnosed Prevalent cases of Bladder cancer
  • Diagnosed Prevalent cases of NMIBC
  • Age-specific Diagnosed Prevalence of NMIBC
  • Tumor (T) stage-specific Diagnosed Prevalence of NMIBC
  • Grade-specific Diagnosed Prevalence of NMIBC, and
  • Risk-specific Diagnosed Prevalence of NMIBC

Key Questions Answered

  • What is the disease risk, burden and unmet needs of NMIBC?
  • What is the historical NMIBC patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of NMIBC at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to NMIBC?
  • Out of the countries mentioned above, which country would have the highest prevalent population of NMIBC during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The NMIBC report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM NMIBC market.
  • Quantify patient populations in the 7MM NMIBC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the specific type of NMIBC that presents the best opportunities for NMIBC therapeutics in each of the markets covered.
  • The NMIBC epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The NMIBC epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents
Product Code: DIEI0934

Table of Contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Non-muscle Invasive Bladder Cancer (NMIBC) Market Overview at a Glance

  • 4.1 Patient Share (%) Distribution of Non-muscle Invasive Bladder Cancer (NMIBC) in 2017
  • 4.2 Patient Share (%) Distribution of Non-muscle Invasive Bladder Cancer (NMIBC) in 2030

5 Disease Background and Overview: Non-muscle Invasive Bladder Cancer (NMIBC)

  • 5.1 Introduction
  • 5.2 Clinical Stages of NMIBC
  • 5.3 Classification of NMIBC
  • 5.4 TNM staging of NMIBC
  • 5.5 Diagnosis of NMIBC
    • 5.5.1 Cystoscopy
    • 5.5.2 Urinary cytology - urinary molecular marker tests
    • 5.5.3 Imaging
    • 5.5.4 Rigid cystoscopy
  • 5.6 European Association of Urology (EAU) Guidelines for Diagnosis of NMIBC
    • 5.6.1 Signs and symptoms
    • 5.6.2 Imaging
    • 5.6.3 Urinary cytology
    • 5.6.4 Urinary molecular marker tests
    • 5.6.5 The potential application of urinary cytology and markers
    • 5.6.6 Cystoscopy
    • 5.6.7 Transurethral resection of TaT1 bladder tumors
    • 5.6.8 New methods of tumor visualization
    • 5.6.9 Second resection
    • 5.6.10 Pathology report
  • 5.7 Predictive Markers of NMIBC
    • 5.7.1 Current markers
    • 5.7.2 Prognostic Biomarkers
    • 5.7.3 Predictive Biomarkers for BCG response

6 Recognized Establishments

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Epidemiology Methodology

8 7MM Total Diagnosed Prevalent cases of Non-muscle Invasive Bladder (NMIBC)

9 7MM Epidemiology of Non-muscle Invasive Bladder Cancer (NMIBC)

  • 9.1 Assumption and Rationale
  • 9.1 United States
    • 9.1.1 Prevalent cases of Bladder Cancer in the United States
    • 9.1.2 Diagnosed Prevalent cases of Bladder Cancer in the United States
    • 9.1.3 Diagnosed Prevalent cases of NMIBC in the United States
    • 9.1.4 Age-specific Diagnosed Prevalence of NMIBC in the United States
    • 9.1.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United States
    • 9.1.6 Grade-specific Diagnosed Prevalence of NMIBC in the United States
    • 9.1.7 Risk-specific Diagnosed Prevalence of NMIBC in the United States
  • 9.2 EU5 Countries
  • 9.3 Germany
    • 9.3.1 Prevalent cases of Bladder Cancer in Germany
    • 9.3.2 Diagnosed Prevalent cases of Bladder Cancer in Germany
    • 9.3.3 Diagnosed Prevalent cases of NMIBC in Germany
    • 9.3.4 Age-specific Diagnosed Prevalence of NMIBC in Germany
    • 9.3.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Germany
    • 9.3.6 Grade-specific Diagnosed Prevalence of NMIBC in Germany
    • 9.3.7 Risk-specific Diagnosed Prevalence of NMIBC in Germany
  • 9.4 France
    • 9.4.1 Prevalent cases of Bladder Cancer in France
    • 9.4.2 Diagnosed Prevalent cases of Bladder Cancer in France
    • 9.4.3 Diagnosed Prevalent cases of NMIBC in France
    • 9.4.4 Age-specific Diagnosed Prevalence of NMIBC in France
    • 9.4.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in France
    • 9.4.6 Grade-specific Diagnosed Prevalence of NMIBC in France
    • 9.4.7 Risk-specific Diagnosed Prevalence of NMIBC in France
  • 9.5 Italy
    • 9.5.1 Prevalent cases of Bladder Cancer in Italy
    • 9.5.2 Diagnosed Prevalent cases of Bladder Cancer in Italy
    • 9.5.3 Diagnosed Prevalent cases of NMIBC in Italy
    • 9.5.4 Age-specific Diagnosed Prevalence of NMIBC in Italy
    • 9.5.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Italy
    • 9.5.6 Grade-specific Diagnosed Prevalence of NMIBC in Italy
    • 9.5.7 Risk-specific Diagnosed Prevalence of NMIBC in Italy
  • 9.6 Spain
    • 9.6.1 Prevalent cases of Bladder Cancer in Spain
    • 9.6.2 Diagnosed Prevalent cases of Bladder Cancer in Spain
    • 9.6.3 Diagnosed Prevalent cases of NMIBC in Spain
    • 9.6.4 Age-specific Diagnosed Prevalence of NMIBC in Spain
    • 9.6.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Spain
    • 9.6.6 Grade-specific Diagnosed Prevalence of NMIBC in Spain
    • 9.6.7 Risk-specific Diagnosed Prevalence of NMIBC in Spain
  • 9.7 United Kingdom
    • 9.7.1 Prevalent cases of Bladder Cancer in the United Kingdom
    • 9.7.2 Diagnosed Prevalent cases of Bladder Cancer in the United Kingdom
    • 9.7.3 Diagnosed Prevalent cases of NMIBC in the United Kingdom
    • 9.7.4 Age-specific Diagnosed Prevalence of NMIBC in the United Kingdom
    • 9.7.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United Kingdom
    • 9.7.6 Grade-specific Diagnosed Prevalence of NMIBC in the United Kingdom
    • 9.7.7 Risk-specific Diagnosed Prevalence of NMIBC in the United Kingdom
  • 9.8 Japan
    • 9.8.1 Prevalent cases of Bladder Cancer in Japan
    • 9.8.2 Diagnosed Prevalent cases of Bladder Cancer in Japan
    • 9.8.3 Diagnosed Prevalent cases of NMIBC in Japan
    • 9.8.4 Age-specific Diagnosed Prevalence of NMIBC in Japan
    • 9.8.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Japan
    • 9.8.6 Grade-specific Diagnosed Prevalence of NMIBC in Japan
    • 9.8.7 Risk-specific Diagnosed Prevalence of NMIBC in Japan

10 Appendix

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

  • Table 1: Summary of Non-muscle invasive bladder cancer (NMIBC), Epidemiology, and Key Events (2017-2030)
  • Table 2: Sub-grouping of the non-invasive urothelial neoplasms with an inverted growth pattern
  • Table 3: Summary of more established urinary markers
  • Table 4: Total Diagnosed Prevalent cases of NMIBC in the 7MM (2017-2030)
  • Table 5: Prevalent cases of Bladder Cancer in the United States (2017-2030)
  • Table 6: Diagnosed Prevalent cases of Bladder Cancer in the United States (2017-2030)
  • Table 7: Diagnosed Prevalent cases of NMIBC in the United States (2017-2030)
  • Table 8: Age-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Table 9: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Table 10: Grade-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Table 11: Risk-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Table 12: Prevalent cases of Bladder Cancer in Germany (2017-2030)
  • Table 13: Diagnosed Prevalent cases of Bladder Cancer in Germany (2017-2030)
  • Table 14: Diagnosed Prevalent cases of NMIBC in Germany (2017-2030)
  • Table 15: Age-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Table 16: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Table 17: Grade-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Table 18: Risk-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Table 19: Prevalent cases of Bladder Cancer in France (2017-2030)
  • Table 20: Diagnosed Prevalent cases of Bladder Cancer in France (2017-2030)
  • Table 21: Diagnosed Prevalent cases of NMIBC in Germany (2017-2030)
  • Table 22: Age-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Table 23: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Table 24: Grade-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Table 25: Risk-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Table 26: Prevalent cases of Bladder Cancer in Italy (2017-2030)
  • Table 27: Diagnosed Prevalent cases of Bladder Cancer in Italy (2017-2030)
  • Table 28: Diagnosed Prevalent cases of NMIBC in Italy (2017-2030)
  • Table 29: Age-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Table 30: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Table 31: Grade-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Table 32: Risk-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Table 33: Prevalent cases of Bladder Cancer in Spain (2017-2030)
  • Table 34: Diagnosed Prevalent cases of Bladder Cancer in Spain (2017-2030)
  • Table 35: Diagnosed Prevalent cases of NMIBC in Spain (2017-2030)
  • Table 36: Age-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Table 37: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Table 38: Grade-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Table 39: Risk-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Table 40: Prevalent cases of Bladder Cancer in the United Kingdom (2017-2030)
  • Table 41: Diagnosed Prevalent cases of Bladder Cancer in the UK (2017-2030)
  • Table 42: Diagnosed Prevalent cases of NMIBC in the UK (2017-2030)
  • Table 43: Age-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Table 44: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Table 45: Grade-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Table 46: Risk-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Table 47: Prevalent cases of Bladder Cancer in Japan (2017-2030)
  • Table 48: Diagnosed Prevalent cases of Bladder Cancer in Japan (2017-2030)
  • Table 49: Diagnosed Prevalent cases of NMIBC in Japan (2017-2030)
  • Table 50: Age-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
  • Table 51: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
  • Table 52: Grade-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
  • Table 53: Risk-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis of Non-muscle Invasive Bladder Cancer
  • Figure 2: Stages of Bladder Cancer
  • Figure 3: Different stages of NMIBC
  • Figure 4: Visualization of potential prognostic and predictive biomarkers in MIBC
  • Figure 5: Total Diagnosed Prevalent cases of NMIBC in the 7MM (2017-2030)
  • Figure 6: Prevalent cases of Bladder Cancer in the United States (2017-2030)
  • Figure 7: Diagnosed Prevalent cases of Bladder Cancer in the United States (2017-2030)
  • Figure 8: Diagnosed Prevalent cases of NMIBC in the United States (2017-2030)
  • Figure 9: Age-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Figure 10: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Figure 11: Grade-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Figure 12: Risk-specific Diagnosed Prevalence of NMIBC in the United States (2017-2030)
  • Figure 13: Prevalent cases of Bladder Cancer in Germany (2017-2030)
  • Figure 14: Diagnosed Prevalent cases of Bladder Cancer in Germany (2017-2030)
  • Figure 15: Diagnosed Prevalent cases of NMIBC in Germany (2017-2030)
  • Figure 16: Age-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Figure 17: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Figure 18: Grade-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Figure 19: Risk-specific Diagnosed Prevalence of NMIBC in Germany (2017-2030)
  • Figure 20: Prevalent cases of Bladder Cancer in France (2017-2030)
  • Figure 21: Diagnosed Prevalent cases of Bladder Cancer in France (2017-2030)
  • Figure 22: Diagnosed Prevalent cases of NMIBC in France (2017-2030)
  • Figure 23: Age-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Figure 24: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Figure 25: Grade-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Figure 26: Risk-specific Diagnosed Prevalence of NMIBC in France (2017-2030)
  • Figure 27: Prevalent cases of Bladder Cancer in Italy (2017-2030)
  • Figure 28: Diagnosed Prevalent cases of Bladder Cancer in Italy (2017-2030)
  • Figure 29: Diagnosed Prevalent cases of NMIBC in Italy (2017-2030)
  • Figure 30: Age-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Figure 31: Tumor (T) stage specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Figure 32: Grade-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Figure 33: Risk-specific Diagnosed Prevalence of NMIBC in Italy (2017-2030)
  • Figure 34: Prevalent cases of Bladder Cancer in Spain (2017-2030)
  • Figure 35: Diagnosed Prevalent cases of Bladder Cancer in Spain (2017-2030)
  • Figure 36: Diagnosed Prevalent cases of NMIBC in Spain (2017-2030)
  • Figure 37: Age-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Figure 38: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Figure 39: Grade-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Figure 40: Risk-specific Diagnosed Prevalence of NMIBC in Spain (2017-2030)
  • Figure 41: Prevalent cases of Bladder Cancer in the United Kingdom (2017-2030)
  • Figure 42: Diagnosed Prevalent cases of Bladder Cancer in the UK (2017-2030)
  • Figure 43: Diagnosed Prevalent cases of NMIBC in the UK (2017-2030)
  • Figure 44: Age-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Figure 45: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Figure 46: Grade-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Figure 47: Risk-specific Diagnosed Prevalence of NMIBC in the UK (2017-2030)
  • Figure 48: Prevalent cases of Bladder Cancer in Japan (2017-2030)
  • Figure 49: Diagnosed Prevalent cases of Bladder Cancer in Japan (2017-2030)
  • Figure 50: Diagnosed Prevalent cases of NMIBC in Japan (2017-2030)
  • Figure 51: Age-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
  • Figure 52: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
  • Figure 53: Grade-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
  • Figure 54: Risk-specific Diagnosed Prevalence of NMIBC in Japan (2017-2030)
Back to Top